ALNY

SEC source: 0001735276-20-000079 · edgardoc.xml · derivative · entry 1

Fanucci Marsha · CIK 0001298814 · Director

10b5-1 filing: Not disclosed

Ownership: Direct

Disclosed balance after: 4,581

Underlying: Common Stock · 4,581 shares

Expires 2030-07-01

SEC source: 0001735276-20-000077 · edgardoc.xml · derivative · entry 1

SHARP PHILLIP A · CIK 0001226295 · Director

10b5-1 filing: Not disclosed

Ownership: Direct

Disclosed balance after: 4,581

Underlying: Common Stock · 4,581 shares

Expires 2030-07-01

SEC source: 0001735276-20-000078 · edgardoc.xml · derivative · entry 1

PAUL STEVEN M · CIK 0001237564 · Director

10b5-1 filing: Not disclosed

Ownership: Direct

Disclosed balance after: 4,581

Underlying: Common Stock · 4,581 shares

Expires 2030-07-01

SEC source: 0001735276-20-000076 · edgardoc.xml · derivative · entry 1

SCHULMAN AMY W · CIK 0001438226 · Director

10b5-1 filing: Not disclosed

Ownership: Direct

Disclosed balance after: 4,581

Underlying: Common Stock · 4,581 shares

Expires 2030-07-01

SEC source: 0001735276-20-000075 · edgardoc.xml · derivative · entry 1

Reitan Colleen F · CIK 0001740730 · Director

10b5-1 filing: Not disclosed

Ownership: Direct

Disclosed balance after: 4,581

Underlying: Common Stock · 4,581 shares

Expires 2030-07-01

SEC source: 0001735276-20-000064 · edgardoc.xml · derivative · entry 8

Vaishnaw Akshay · CIK 0001458494 · President, R&D

10b5-1 filing: Not disclosed

Ownership: Direct

Disclosed balance after: 4,309

Underlying: Common Stock · 970 shares

Expires 2026-12-20

Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event.

F1 · kind: All sales reported on this Form 4 were made pursuant to a Rule 10b5-1 trading plan adopted by the reporting person on December 04, 2019.

F8 · derivative.exercise_date: The stock option vested as to 25% of the shares on the 1st anniversary of the date of the stock option grant and as to an additional 6.25% of the shares each successive three month period thereafter.

SEC source: 0001735276-20-000064 · edgardoc.xml · nonDerivative · entry 6

Vaishnaw Akshay · CIK 0001458494 · President, R&D

10b5-1 filing: Not disclosed

Ownership: Direct

Disclosed balance after: 14,119

F1 · kind: All sales reported on this Form 4 were made pursuant to a Rule 10b5-1 trading plan adopted by the reporting person on December 04, 2019.

F6 · price: Sale prices ranged from $152.84 to $153.34.

SEC source: 0001735276-20-000064 · edgardoc.xml · nonDerivative · entry 5

Vaishnaw Akshay · CIK 0001458494 · President, R&D

10b5-1 filing: Not disclosed

Ownership: Direct

Disclosed balance after: 14,314

F1 · kind: All sales reported on this Form 4 were made pursuant to a Rule 10b5-1 trading plan adopted by the reporting person on December 04, 2019.

F5 · price: Sale prices ranged from $151.58 to $152.56.

SEC source: 0001735276-20-000064 · edgardoc.xml · nonDerivative · entry 4

Vaishnaw Akshay · CIK 0001458494 · President, R&D

10b5-1 filing: Not disclosed

Ownership: Direct

Disclosed balance after: 14,648

F1 · kind: All sales reported on this Form 4 were made pursuant to a Rule 10b5-1 trading plan adopted by the reporting person on December 04, 2019.

F4 · price: Sale prices ranged from $150.18 to $150.53.

SEC source: 0001735276-20-000064 · edgardoc.xml · nonDerivative · entry 3

Vaishnaw Akshay · CIK 0001458494 · President, R&D

10b5-1 filing: Not disclosed

Ownership: Direct

Disclosed balance after: 14,828

F1 · kind: All sales reported on this Form 4 were made pursuant to a Rule 10b5-1 trading plan adopted by the reporting person on December 04, 2019.

F3 · price: Sale prices ranged from $149.07 to $149.96.

SEC source: 0001735276-20-000064 · edgardoc.xml · nonDerivative · entry 2

Vaishnaw Akshay · CIK 0001458494 · President, R&D

10b5-1 filing: Not disclosed

Ownership: Direct

Disclosed balance after: 14,911

F1 · kind: All sales reported on this Form 4 were made pursuant to a Rule 10b5-1 trading plan adopted by the reporting person on December 04, 2019.

F2 · price: Sale prices ranged from $148.01 to $148.78.

SEC source: 0001735276-20-000064 · edgardoc.xml · nonDerivative · entry 1

Vaishnaw Akshay · CIK 0001458494 · President, R&D

10b5-1 filing: Not disclosed

Ownership: Direct

Disclosed balance after: 15,089

Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event.

F1 · kind: All sales reported on this Form 4 were made pursuant to a Rule 10b5-1 trading plan adopted by the reporting person on December 04, 2019.

SEC source: 0001735276-20-000062 · edgardoc.xml · derivative · entry 6

MARAGANORE JOHN · CIK 0001180432 · Director · Chief Executive Officer

10b5-1 filing: Not disclosed

Ownership: Direct

Disclosed balance after: 69,530

Underlying: Common Stock · 34,765 shares

Expires 2020-12-08

Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event.

F1 · kind: All sales reported on this Form 4 were made pursuant to a Rule 10b5-1 trading plan adopted by the reporting person on December 3, 2019. The 34,765 options exercised and sold by the reporting person were due to expire on December 8, 2020.

F6 · derivative.exercise_date: The stock option vested as to 25% of the shares on the 1st anniversary of the date of the stock option grant and as to an additional 6.25% of the shares each successive three month period thereafter.

SEC source: 0001735276-20-000062 · edgardoc.xml · nonDerivative · entry 4

MARAGANORE JOHN · CIK 0001180432 · Director · Chief Executive Officer

10b5-1 filing: Not disclosed

Ownership: Direct

Disclosed balance after: 197,589

F1 · kind: All sales reported on this Form 4 were made pursuant to a Rule 10b5-1 trading plan adopted by the reporting person on December 3, 2019. The 34,765 options exercised and sold by the reporting person were due to expire on December 8, 2020.

F4 · price: Sale prices ranged from $143.92 to $144.92.

SEC source: 0001735276-20-000062 · edgardoc.xml · nonDerivative · entry 3

MARAGANORE JOHN · CIK 0001180432 · Director · Chief Executive Officer

10b5-1 filing: Not disclosed

Ownership: Direct

Disclosed balance after: 202,602

F1 · kind: All sales reported on this Form 4 were made pursuant to a Rule 10b5-1 trading plan adopted by the reporting person on December 3, 2019. The 34,765 options exercised and sold by the reporting person were due to expire on December 8, 2020.

F3 · price: Sale prices ranged from $142.92 to $143.91.

SEC source: 0001735276-20-000062 · edgardoc.xml · nonDerivative · entry 2

MARAGANORE JOHN · CIK 0001180432 · Director · Chief Executive Officer

10b5-1 filing: Not disclosed

Ownership: Direct

Disclosed balance after: 218,917

F1 · kind: All sales reported on this Form 4 were made pursuant to a Rule 10b5-1 trading plan adopted by the reporting person on December 3, 2019. The 34,765 options exercised and sold by the reporting person were due to expire on December 8, 2020.

F2 · price: Sale prices ranged from $141.92 to $142.89.

SEC source: 0001735276-20-000062 · edgardoc.xml · nonDerivative · entry 1

MARAGANORE JOHN · CIK 0001180432 · Director · Chief Executive Officer

10b5-1 filing: Not disclosed

Ownership: Direct

Disclosed balance after: 232,354

Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event.

F1 · kind: All sales reported on this Form 4 were made pursuant to a Rule 10b5-1 trading plan adopted by the reporting person on December 3, 2019. The 34,765 options exercised and sold by the reporting person were due to expire on December 8, 2020.

SEC source: 0001735276-20-000060 · edgardoc.xml · derivative · entry 5

Greene Barry E · CIK 0001291963 · President

10b5-1 filing: Not disclosed

Ownership: Direct

Disclosed balance after: 66,795

Underlying: Common Stock · 22,265 shares

Expires 2020-12-08

Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event.

F1 · kind: All sales reported on this Form 4 were made pursuant to a Rule 10b5-1 trading plan adopted by the reporting person on February 13, 2020. The 22,265 options exercised and sold by the reporting person were due to expire on December 8, 2020.

F4 · derivative.exercise_date: The stock option vests as to 25% of the shares on the 1st anniversary of the date of the stock option grant and as to an additional 6.25% of the shares each successive three month period thereafter.

SEC source: 0001735276-20-000060 · edgardoc.xml · nonDerivative · entry 2

Greene Barry E · CIK 0001291963 · President

10b5-1 filing: Not disclosed

Ownership: Direct

Disclosed balance after: 62,236

F1 · kind: All sales reported on this Form 4 were made pursuant to a Rule 10b5-1 trading plan adopted by the reporting person on February 13, 2020. The 22,265 options exercised and sold by the reporting person were due to expire on December 8, 2020.

SEC source: 0001735276-20-000060 · edgardoc.xml · nonDerivative · entry 1

Greene Barry E · CIK 0001291963 · President

10b5-1 filing: Not disclosed

Ownership: Direct

Disclosed balance after: 84,501

Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event.

F1 · kind: All sales reported on this Form 4 were made pursuant to a Rule 10b5-1 trading plan adopted by the reporting person on February 13, 2020. The 22,265 options exercised and sold by the reporting person were due to expire on December 8, 2020.

SEC source: 0001735276-20-000059 · edgardoc.xml · derivative · entry 9

Greenstreet Yvonne · CIK 0001446125 · Chief Operating Officer

10b5-1 filing: Not disclosed

Ownership: Direct

Disclosed balance after: 75,000

Underlying: Common Stock · 50,000 shares

Expires 2026-09-18

Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event.

F1 · kind: All sales reported on this Form 4 were made pursuant to a Rule 10b5-1 trading plan adopted by the reporting person on March 02, 2020.

F3 · derivative.exercise_date: The stock option vests as to 25% of the shares on the 1st anniversary of the date of the stock option grant and as to an additional 6.25% of the shares each successive three month period thereafter.

SEC source: 0001735276-20-000059 · edgardoc.xml · nonDerivative · entry 5

Greenstreet Yvonne · CIK 0001446125 · Chief Operating Officer

10b5-1 filing: Not disclosed

Ownership: Direct

Disclosed balance after: 4,820

F1 · kind: All sales reported on this Form 4 were made pursuant to a Rule 10b5-1 trading plan adopted by the reporting person on March 02, 2020.

SEC source: 0001735276-20-000059 · edgardoc.xml · nonDerivative · entry 4

Greenstreet Yvonne · CIK 0001446125 · Chief Operating Officer

10b5-1 filing: Not disclosed

Ownership: Direct

Disclosed balance after: 54,820

Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event.

F1 · kind: All sales reported on this Form 4 were made pursuant to a Rule 10b5-1 trading plan adopted by the reporting person on March 02, 2020.

SEC source: 0001735276-20-000059 · edgardoc.xml · derivative · entry 8

Greenstreet Yvonne · CIK 0001446125 · Chief Operating Officer

10b5-1 filing: Not disclosed

Ownership: Direct

Disclosed balance after: 14,064

Underlying: Common Stock · 1,561 shares

Expires 2026-12-20

Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event.

F1 · kind: All sales reported on this Form 4 were made pursuant to a Rule 10b5-1 trading plan adopted by the reporting person on March 02, 2020.

F3 · derivative.exercise_date: The stock option vests as to 25% of the shares on the 1st anniversary of the date of the stock option grant and as to an additional 6.25% of the shares each successive three month period thereafter.

SEC source: 0001735276-20-000059 · edgardoc.xml · derivative · entry 7

Greenstreet Yvonne · CIK 0001446125 · Chief Operating Officer

10b5-1 filing: Not disclosed

Ownership: Direct

Disclosed balance after: 650

Underlying: Common Stock · 6,250 shares

Expires 2026-12-20

Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event.

F1 · kind: All sales reported on this Form 4 were made pursuant to a Rule 10b5-1 trading plan adopted by the reporting person on March 02, 2020.

SEC source: 0001735276-20-000059 · edgardoc.xml · nonDerivative · entry 3

Greenstreet Yvonne · CIK 0001446125 · Chief Operating Officer

10b5-1 filing: Not disclosed

Ownership: Direct

Disclosed balance after: 4,820

F1 · kind: All sales reported on this Form 4 were made pursuant to a Rule 10b5-1 trading plan adopted by the reporting person on March 02, 2020.

SEC source: 0001735276-20-000059 · edgardoc.xml · nonDerivative · entry 2

Greenstreet Yvonne · CIK 0001446125 · Chief Operating Officer

10b5-1 filing: Not disclosed

Ownership: Direct

Disclosed balance after: 12,631

Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event.

F1 · kind: All sales reported on this Form 4 were made pursuant to a Rule 10b5-1 trading plan adopted by the reporting person on March 02, 2020.

SEC source: 0001735276-20-000059 · edgardoc.xml · nonDerivative · entry 1

Greenstreet Yvonne · CIK 0001446125 · Chief Operating Officer

10b5-1 filing: Not disclosed

Ownership: Direct

Disclosed balance after: 11,070

Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event.

F1 · kind: All sales reported on this Form 4 were made pursuant to a Rule 10b5-1 trading plan adopted by the reporting person on March 02, 2020.

SEC source: 0001735276-20-000056 · edgardoc.xml · derivative · entry 4

KEATING LAURIE · CIK 0001620743 · EVP, Chief Legal Officer

10b5-1 filing: Not disclosed

Ownership: Direct

Disclosed balance after: 42,000

Underlying: Common Stock · 10,000 shares

Expires 2024-09-22

Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event.

F1 · kind: All sales reported on this Form 4 were made pursuant to a Rule 10b5-1 trading plan adopted by the reporting person on November 26, 2019.

F3 · derivative.exercise_date: The stock option vests as to 25% of the shares on the 1st anniversary of the date of the stock option grant and as to an additional 6.25% of the shares each successive three month period thereafter.

SEC source: 0001735276-20-000056 · edgardoc.xml · nonDerivative · entry 2

KEATING LAURIE · CIK 0001620743 · EVP, Chief Legal Officer

10b5-1 filing: Not disclosed

Ownership: Direct

Disclosed balance after: 14,492

F1 · kind: All sales reported on this Form 4 were made pursuant to a Rule 10b5-1 trading plan adopted by the reporting person on November 26, 2019.

SEC source: 0001735276-20-000056 · edgardoc.xml · nonDerivative · entry 1

KEATING LAURIE · CIK 0001620743 · EVP, Chief Legal Officer

10b5-1 filing: Not disclosed

Ownership: Direct

Disclosed balance after: 24,492

Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event.

F1 · kind: All sales reported on this Form 4 were made pursuant to a Rule 10b5-1 trading plan adopted by the reporting person on November 26, 2019.

SEC source: 0001735276-20-000055 · edgardoc.xml · derivative · entry 6

Vaishnaw Akshay · CIK 0001458494 · President, R&D

10b5-1 filing: Not disclosed

Ownership: Direct

Disclosed balance after: 5,279

Underlying: Common Stock · 971 shares

Expires 2026-12-20

Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event.

F1 · kind: All sales reported on this Form 4 were made pursuant to a Rule 10b5-1 trading plan adopted by the reporting person on December 04, 2019.

F3 · derivative.exercise_date: The stock option vests as to 25% of the shares on the 1st anniversary of the date of the stock option grant and as to an additional 6.25% of the shares each successive three month period thereafter.

SEC source: 0001735276-20-000055 · edgardoc.xml · derivative · entry 5

Vaishnaw Akshay · CIK 0001458494 · President, R&D

10b5-1 filing: Not disclosed

Ownership: Direct

Disclosed balance after: 0

Underlying: Common Stock · 21,000 shares

Expires 2026-12-20

Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event.

F1 · kind: All sales reported on this Form 4 were made pursuant to a Rule 10b5-1 trading plan adopted by the reporting person on December 04, 2019.

SEC source: 0001735276-20-000055 · edgardoc.xml · nonDerivative · entry 3

Vaishnaw Akshay · CIK 0001458494 · President, R&D

10b5-1 filing: Not disclosed

Ownership: Direct

Disclosed balance after: 14,119

F1 · kind: All sales reported on this Form 4 were made pursuant to a Rule 10b5-1 trading plan adopted by the reporting person on December 04, 2019.

SEC source: 0001735276-20-000055 · edgardoc.xml · nonDerivative · entry 2

Vaishnaw Akshay · CIK 0001458494 · President, R&D

10b5-1 filing: Not disclosed

Ownership: Direct

Disclosed balance after: 36,090

Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event.

F1 · kind: All sales reported on this Form 4 were made pursuant to a Rule 10b5-1 trading plan adopted by the reporting person on December 04, 2019.

SEC source: 0001735276-20-000055 · edgardoc.xml · nonDerivative · entry 1

Vaishnaw Akshay · CIK 0001458494 · President, R&D

10b5-1 filing: Not disclosed

Ownership: Direct

Disclosed balance after: 35,119

Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event.

F1 · kind: All sales reported on this Form 4 were made pursuant to a Rule 10b5-1 trading plan adopted by the reporting person on December 04, 2019.

SEC source: 0001735276-20-000048 · edgardoc.xml · nonDerivative · entry 3

Greenstreet Yvonne · CIK 0001446125 · Chief Operating Officer

10b5-1 filing: Not disclosed

Ownership: Direct

Disclosed balance after: 4,820

F2 · kind: Represents shares automatically sold by the Company on behalf of the reporting person pursuant to a mandatory sell-to-cover provision in the PSU award agreement required to cover minimum statutory tax withholding obligations that became due upon the vesting event.

SEC source: 0001735276-20-000048 · edgardoc.xml · nonDerivative · entry 2

Greenstreet Yvonne · CIK 0001446125 · Chief Operating Officer

10b5-1 filing: Not disclosed

Ownership: Direct

Disclosed balance after: 4,918

F2 · kind: Represents shares automatically sold by the Company on behalf of the reporting person pursuant to a mandatory sell-to-cover provision in the PSU award agreement required to cover minimum statutory tax withholding obligations that became due upon the vesting event.

SEC source: 0001735276-20-000048 · edgardoc.xml · nonDerivative · entry 1

Greenstreet Yvonne · CIK 0001446125 · Chief Operating Officer

10b5-1 filing: Not disclosed

Ownership: Direct

Disclosed balance after: 7,333

F1 · kind: On February 28, 2019, the reporting person was granted performance-based restricted stock units (PSU) in connection with the 2018 year-end compensation review. This PSU award vests in three equal installments upon the later of one year from the date of grant and the achievement of each of three specific clinical development, regulatory or commercial events. One third of the shares subject to release under the PSU award vested upon the filing by the Company of its fourth NDA with the FDA, as determined by the compensation committee of the Company effective April 7, 2020.

SEC source: 0001735276-20-000049 · edgardoc.xml · nonDerivative · entry 3

Greene Barry E · CIK 0001291963 · President

10b5-1 filing: Not disclosed

Ownership: Direct

Disclosed balance after: 62,236

F2 · kind: Represents shares automatically sold by the Company on behalf of the reporting person pursuant to a mandatory sell-to-cover provision in the PSU award agreement required to cover minimum statutory tax withholding obligations that became due upon the vesting event.

SEC source: 0001735276-20-000049 · edgardoc.xml · nonDerivative · entry 2

Greene Barry E · CIK 0001291963 · President

10b5-1 filing: Not disclosed

Ownership: Direct

Disclosed balance after: 62,300

F2 · kind: Represents shares automatically sold by the Company on behalf of the reporting person pursuant to a mandatory sell-to-cover provision in the PSU award agreement required to cover minimum statutory tax withholding obligations that became due upon the vesting event.

SEC source: 0001735276-20-000049 · edgardoc.xml · nonDerivative · entry 1

Greene Barry E · CIK 0001291963 · President

10b5-1 filing: Not disclosed

Ownership: Direct

Disclosed balance after: 63,899

F1 · kind: On February 28, 2019, the reporting person was granted performance-based restricted stock units (PSU) in connection with the 2018 year-end compensation review. This PSU award vests in three equal installments upon the later of one year from the date of grant and the achievement of each of three specific clinical development, regulatory or commercial events. One third of the shares subject to release under the PSU award vested upon the filing by the Company of its fourth NDA with the FDA, as determined by the compensation committee of the Company effective April 7, 2020.

SEC source: 0001735276-20-000047 · edgardoc.xml · nonDerivative · entry 3

KEATING LAURIE · CIK 0001620743 · EVP, Chief Legal Officer

10b5-1 filing: Not disclosed

Ownership: Direct

Disclosed balance after: 14,492

F2 · kind: Represents shares automatically sold by the Company on behalf of the reporting person pursuant to a mandatory sell-to-cover provision in the PSU award agreement required to cover minimum statutory tax withholding obligations that became due upon the vesting event.

SEC source: 0001735276-20-000047 · edgardoc.xml · nonDerivative · entry 2

KEATING LAURIE · CIK 0001620743 · EVP, Chief Legal Officer

10b5-1 filing: Not disclosed

Ownership: Direct

Disclosed balance after: 14,567

F2 · kind: Represents shares automatically sold by the Company on behalf of the reporting person pursuant to a mandatory sell-to-cover provision in the PSU award agreement required to cover minimum statutory tax withholding obligations that became due upon the vesting event.

SEC source: 0001735276-20-000047 · edgardoc.xml · nonDerivative · entry 1

KEATING LAURIE · CIK 0001620743 · EVP, Chief Legal Officer

10b5-1 filing: Not disclosed

Ownership: Direct

Disclosed balance after: 16,425

F1 · kind: On February 28, 2019, the reporting person was granted performance-based restricted stock units (PSU) in connection with the 2018 year-end compensation review. This PSU award vests in three equal installments upon the later of one year from the date of grant and the achievement of each of three specific clinical development, regulatory or commercial events. One third of the shares subject to release under the PSU award vested upon the filing by the Company of its fourth NDA with the FDA, as determined by the compensation committee of the Company effective April 7, 2020.

SEC source: 0001735276-20-000046 · edgardoc.xml · nonDerivative · entry 3

MARAGANORE JOHN · CIK 0001180432 · Director · Chief Executive Officer

10b5-1 filing: Not disclosed

Ownership: Direct

Disclosed balance after: 197,589

F2 · kind: Represents shares automatically sold by the Company on behalf of the reporting person pursuant to a mandatory sell-to-cover provision in the PSU award agreement required to cover minimum statutory tax withholding obligations that became due upon the vesting event.

SEC source: 0001735276-20-000046 · edgardoc.xml · nonDerivative · entry 2

MARAGANORE JOHN · CIK 0001180432 · Director · Chief Executive Officer

10b5-1 filing: Not disclosed

Ownership: Direct

Disclosed balance after: 197,845

F2 · kind: Represents shares automatically sold by the Company on behalf of the reporting person pursuant to a mandatory sell-to-cover provision in the PSU award agreement required to cover minimum statutory tax withholding obligations that became due upon the vesting event.

SEC source: 0001735276-20-000046 · edgardoc.xml · nonDerivative · entry 1

MARAGANORE JOHN · CIK 0001180432 · Director · Chief Executive Officer

10b5-1 filing: Not disclosed

Ownership: Direct

Disclosed balance after: 204,160

F1 · kind: On February 28, 2019, the reporting person was granted performance-based restricted stock units (PSU) in connection with the 2018 year-end compensation review. This PSU award vests in three equal installments upon the later of one year from the date of grant and the achievement of each of three specific clinical development, regulatory or commercial events. One third of the shares subject to release under the PSU award vested upon the filing by the Company of its fourth NDA with the FDA, as determined by the compensation committee of the Company effective April 7, 2020.

SEC source: 0001735276-20-000045 · edgardoc.xml · nonDerivative · entry 3

Vaishnaw Akshay · CIK 0001458494 · President, R&D

10b5-1 filing: Not disclosed

Ownership: Direct

Disclosed balance after: 14,119

F2 · kind: Represents shares automatically sold by the Company on behalf of the reporting person pursuant to a mandatory sell-to-cover provision in the PSU award agreement required to cover minimum statutory tax withholding obligations that became due upon the vesting event.

SEC source: 0001735276-20-000045 · edgardoc.xml · nonDerivative · entry 2

Vaishnaw Akshay · CIK 0001458494 · President, R&D

10b5-1 filing: Not disclosed

Ownership: Direct

Disclosed balance after: 14,217

F2 · kind: Represents shares automatically sold by the Company on behalf of the reporting person pursuant to a mandatory sell-to-cover provision in the PSU award agreement required to cover minimum statutory tax withholding obligations that became due upon the vesting event.